GTHX G1 Therapeutics
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 2, 2021 (July 27, 2021)
G1 THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
|(State or other jurisdiction|
700 Park Offices Drive
Research Triangle Park, NC
|(Address of principal executive offices)||(zip code)|
Registrant’s telephone number, including area code: (919) 213-9835
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Name of each exchange
|Common stock, $0.0001 par value||GTHX||The Nasdaq Stock Market|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging Growth Company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Appointment of New Executive Officer
On August 2, 2021, G1 Therapeutics, Inc. (the “Company”) announced the appointment of Andrew Perry as Chief Commercial Officer. Mr. Perry joins the Company from ViiV Healthcare NA, a joint venture majority-owned by GlaxoSmithKline, where he served as Vice President, US Marketing. Mr. Perry brings nearly 25 years of leadership experience in product commercialization and managed markets to the Company, having led multiple successful product launches and growing brands.
Departure of Executive Officer
On July 27, 2021, the Company and Soma Gupta, Chief Commercial Officer, mutually agreed to separate. Ms. Gupta left the Company for personal and professional reasons.
Financial Statements and Exhibits.
|99.1||Press Release dated August 2, 2021|
|104||Cover Page Interactive Data File (embedded within the Inline XBRL document)|
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|G1 THERAPEUTICS, INC.|
/s/ James Stillman Hanson
|James Stillman Hanson|
Date: August 2, 2021